Hong Kong vs United States: The number of people with susceptibility test result for rifampicin
Hong Kong
94.83
in 2021
United States
94.32
in 2021
Hong Kong rank
52nd
United States rank
53rd
The number of people with susceptibility test result for rifampicin over time
- Hong Kong
- United States
How they compare
Hong Kong currently reports 94.83 against 94.32 in United States, a difference of 0.51.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Hong Kong ahead.
Hong Kong ranks 52nd and United States ranks 53rd of 146 countries.
Hong Kong has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Hong Kong | United States | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 96.18 | 90.97 | 5.22 | Hong Kong |
| 2020s | 94.72 | 94.51 | 0.2014 | Hong Kong |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Hong Kong or United States?
- Hong Kong, at 94.83 against 94.32 in United States as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Hong Kong and United States?
- 0.51, with Hong Kong ahead.
- How many years of comparable data are there for Hong Kong and United States?
- 5 years are reported by both, from 2017 to 2021.
- How do Hong Kong and United States rank globally for the number of people with susceptibility test result for rifampicin?
- Hong Kong ranks 52nd and United States ranks 53rd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.